New drug combo tested for tough pancreatic cancer
NCT ID NCT02021422
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested whether adding the drug anakinra to standard chemotherapy is safe for people with metastatic pancreatic cancer. Thirteen adults with advanced disease received the combination. The main goal was to check for side effects, not to see if it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- anakinra (Kineret) plus standard chemotherapy (oxaliplatin, irinotecan, fluorouracil)
- What this could lead to
- If this combination proves safe, it could point toward a new treatment option for metastatic pancreatic cancer.
- What could go wrong
- This is a very early, small Phase 1 safety trial with only 13 participants. It cannot prove the treatment works, and side effects or lack of benefit are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Baylor Sammons Cancer Center
Dallas, Texas, 75246, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill rouse the immune system against pancreatic cancer?
- Can a new ultrasound technique spot hidden pancreatic cancers earlier?
- Can an immunotherapy cocktail slow pancreatic cancer? a new trial aims to find out.
- A simple breath test might spot multiple cancers before symptoms appear
- Can High-Dose vitamin c boost Chemo's punch against pancreatic cancer?
- Can High-Dose vitamin c boost chemo against pancreatic cancer?